InMed Pharmaceuticals Inc. (MTRI) stock
MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
$18.60+0.25 (+1.36%)
Close on Nov 13, 2026Market cap $102.18MP/E –Yield –
InMed Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
InMed Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $2.67M, up 7.8% year over year. For fiscal 2026 it was $3.03M, up 7.3% from the year before. The highest annual figure on record is $7.28M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $3.03M | +7.3% |
| FY2025 | Jun 30, 2025 | $2.82M | -12.3% |
| FY2024 | Jun 30, 2024 | $3.22M | -13.8% |
| FY2023 | Jun 30, 2023 | $3.73M | -48.8% |
| FY2022 | Jun 30, 2022 | $7.28M | +36.4% |
| FY2021 | Jun 30, 2021 | $5.34M | -8.1% |
| FY2020 | Jun 30, 2020 | $5.81M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $206.02K | -64.2% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $805.74K | +39.6% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $1.02M | +140.4% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $630.64K | -29.6% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $575.46K | -17.8% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $577.25K | -12.4% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $425.37K | -35.2% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $895.18K | +46.8% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $700.15K | -45.8% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $658.87K | +5.6% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $656.76K | -25.2% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $609.79K | -28.4% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $1.29M | -6.3% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $623.74K | -58.4% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $878.30K | -49.9% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $851.36K | -66.4% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $1.38M | -7.6% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $1.50M | -12.6% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $1.75M | -1.1% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $2.54M | +170.5% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $1.49M | +63.7% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $1.72M | +77.4% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $1.77M | +39.0% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $937.95K | -41.6% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $911.16K | -53.6% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $967.61K | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $1.27M | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $1.61M | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $1.96M | – |
See a number that looks wrong?